Sertindole for the treatment of schizophrenia

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 18, 2010, Pages 3053-3064

  Azorin, Jean Michel ^a   Kaladjian, Arthur ^a   Fakra, Eric ^a   Adida, Marc ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

Efficacy; Safety; Schizophrenia; Second generation antipsychotic; Sertindole; Tolerability

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; HALOPERIDOL; KETOCONAZOLE; MACROLIDE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; QUETIAPINE; QUINIDINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE;

AKATHISIA; BRAIN FUNCTION; BRIEF PSYCHIATRIC RATING SCALE; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; COGNITION; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ELECTROCARDIOGRAPHY MONITORING; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HEALTH SURVEY; HEART ARRHYTHMIA; HEART DEATH; HUMAN; INSOMNIA; MENTAL DISEASE; MORTALITY; NAUSEA; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NOSE CONGESTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT PROLONGATION; RECEPTOR OCCUPANCY; REVIEW; RHINITIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; SUDDEN DEATH; SUICIDE; SUICIDE ATTEMPT; SYNCOPE; TORSADE DES POINTES; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; IMIDAZOLES; INDOLES; MEDICATION ADHERENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 78649291110     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.536217     Document Type: Review

References (99)

1. Jablensky A, Sartorius, Eruberg G, et al. Schizophrenia; manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monograph Suppl 1992;20:1-97
2. Cannon M, Jones P. Schizophrenia. J Neurol Neurosurg Psychiatr 1996;20:604-13
3. Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 1984;10:300-12
4. Hafner H, Maurer K, Loffler W, et al. Modeling the early course of schizophrenia. Schizophr Bull 2003;29:325-40
5. Knoll JL, Garver DL, Ramberg JE, et al. Heterogeneity of the psychoses: is there a neurogenerative psychosis? Schizophr Bull 1988;24:365-79
6. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999;46:729-39
7. Weinberger DR, Gallhofer S. Cognitive function in schizophrenia. Int Clin Psychopharmacol 1997;12:S29-36
8. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr Bull 1999;25:173-82
9. Brown S, Inskip H, Barraclough B. Courses of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-17
10. Davies LM, Drummond MF. Economics and schizophrenia: the red cost. Br J Psychiatry 1994;25(Suppl):18-21
11. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64 •• The first meta-analysis to show that some second-generation antipsychotics (SGAs) were more efficacious than first-generation antipsychotics (FGAs) and did not constitute a homogeneous group.
12. Geddes J, Freemantle N, Harrison P, et al.; for the National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6 •• The first of the meta-analyses comparing the efficacy and safety of SGAs versus FGAs and which found no clear evidence of any advantage of the former over the latter.
13. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41 •• An outstanding meta-analysis that clearly demonstrated that SGAs differed in many properties and confirmed that they were not a homogeneous class.
14. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38 •• A comprehensive review on the comparative effectiveness of SGAs and FGAs, which also found both classes to be very heterogeneous.
15. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93
16. Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 2004;18(Suppl 2):19-30
17. Cincotta SL, Rodefer JS. Emerging role of sertindole in the management of schizophrenia. Neuropsychiatr Dis Treat 2010;6:429-41 •• A recent review that provides valuable information on the role of sertindole in the context of current pharmacological treatment for schizophrenia.
18. Murdoch D, Keating GM. Sertindole. A review of its use in schizophrenia. CNS Drugs 2006;20:233-55 •• One of the most complete reviews on both preclinical and clinical findings concerning sertindole, published in 2006.
19. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, 'just the facts' 5. Treatment and prevention. Past, present, and future. Schizophr Res 2010;122:1-23
20. Davis JM, Leucht S. Has research informed us on the practical drug treatment of schizophrenia? Schizophr Bull 2008;34:403-5
21. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010;55:117-25
22. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91
23. Chiodo LA, Bunney BS. Possible mechanisms by which repeated clozapine administration differentially affect the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 1985;5:2539-44
24. Thomas SHL, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010;122:345-55
25. Tamminga CA, Mack RJ, Granneman R, et al. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacology 1997;12(Suppl 1):S29-35 •• An informative review on the clinical trials included in the development program of sertindole.
26. Hale AS. A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 1998;13(Suppl 3):S65-70 •• A detailed review on sertindole safety and side effects, published at the time of its launch.
27. Kasper S. Sertindole: safety and tolerability profile. Int J Psychiatry Clin Pract 2002;6(Suppl 1):S27-32 • A review of the tolerability profile of sertindole.
28. Kane JM, Tamminga CA. Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Invest Drugs 1997;6:1729-41 •• A clearly presented and well-documented review of sertindole profile, published at the time it was launched.
29. Muscatello MRA, Bruno A, Pandolfo GL, et al. Emerging treatments in the management of schizophrenia. Focus on sertindole. Drug des Dev Ther 2010;4:187-201
30. Arnt J, Skarsfeldt T. Do novel antipsychotic have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101
31. Sanchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo parmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991;22:239-50
32. Hyttel J, Nielsen JP, Nowak G. The acute affect of sertindole on brain 5HT2, D2 and alpha1 receptors (ex vivo radioreceptor binding studies). J Neural Trans 1992;89:61-9
33. Skarsfeldt J. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 1992;10:25-32
34. Hietala J, Kuoppamaki M, Majasuo H, et al. Sertindole is a serotonin 5HT2c inverse agonist and decrease agonist but not antagonist binding to 5HT2c receptors after chronic treatment. Psychopharmacology 2001;157:180-7
35. Mork A, Witten LM, Arnt J. Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology 2009;206:39-49
36. Petit-Taboue MC, Landeau B, Barre L, et al. Parametric PET imaging of 5HT2 A receptor distribution with 18 F-setoperone in the normal human cortex. J Nucl Med 1999;40:25-32
37. Nyberg S, Olsson H, Nilsson U, et al. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology 2002;162:37-41
38. Pilowsky LS, O'Connell P, Davies N, et al. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole: a 123 I - IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1997;130:152-8
39. Kasper S, Tauscher J, Kufferle B, et al. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol: a 123 I - IBZM SPECT study. Psychopharmacology (Berl) 1998;136:367-73
40. Buchsbaum MS, Haznedar M, Newmark RE, et al. FDG and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. Schizophr Res 2009;114:161-74
41. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology 1996;124:126-33
42. Didriksen M, Kreilgaard M, Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 2006;542:108-15
43. Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match position paradigm. Eur J Pharmacol 1995;281:241-50
44. Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacol 2008;33:2657-66
45. Rampe D, Murawksy MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998;262:788-93
46. Haverkamp W, Eckardt L, Matz J. Sertindole: cardiac electrophysiological profile. Int J Psychiatry Clin Pract 2002;6(Suppl 1):S11-20
47. Lindstrom E, Farde L, Eberhard J, et al. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neurospychopharmacol 2005;8:615-29
48. Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointe: low torsado-genic potential despite QT prolongation. J Pharmacol Exp Ther 2002;300:64-71
49. Thomsen MB, Volders PGA, Stengl M, et al. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J Pharmacol Exp Ther 2003;307:776-84
50. Titier K, Canal M, Deridet E, et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 2004;199:52-60
51. Wong SL, Linnen P, Mack R, et al. Effects of food, antacid and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Biopharm Drug Dispos 1997;18:533-41
52. Wong SL, Cao G, Mack RJ, et al. Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin Pharmacol Ther 1997;18:533-41
53. Wong SL, Menacherry S, Mulford D, et al. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol 1997;52:223-7
54. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics (PtI): pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85
55. Wong SL, Granneman GR. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short-term dose-escalation studies. J Pharm Sci 1998;87:1629-31
56. Ouellet D, Cao G, Staser J, et al. Population pharmacokinetics of sertindole in patients with schizophrenia [abstract n PII-50]. Presented at the 99th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics 5-8 March 1997; San Diego, CA, USA
57. H. Lundbeck A/S. Sertindole: summary of product characteristics. Copenhagen: H. Lundbeck A/S, 2005
58. Data on file, H. Lundbeck A/S, 2006
59. McEvoy J, Borison R, Small J, et al. The efficacy and tolerability of sertindole in schizophrenic patients: a pilot, double-blind, placebo-controlled, dose ranging study [abstract]. Schizophr Res 1993;9:244
60. van Kammen DP, Mc Evoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-75
61. Hale A, Azorin JM, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatr Clin Pract 2000;4:55-62 (Pubitemid 30198337)
62. Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998;34:61-9
63. Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int J Psychopharmacol 2006;21:49-56
64. Kane JM, Potkin SG, Daniel DG, Buckley P. A double-bind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry 2010 Jul. 27 [Epub ahead of print]
65. Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009;14:429-47
66. Komossa K, Rummel-Kluge C, Hunger H, et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;15:CD006752
67. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63
68. Gallhofer B, Jaanson P, Mittoux A, et al. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007;40:275-86
69. Chang RJ, Swann AC, Becker LA, et al. A one year, controlled cost-effectiveness study comparing sertindole and haloperidol in stable schizophrenic patients. Poster presented at the 7th World Congress of Biological Psychiatry July 1-6 2001; Berlin, Germany
70. Azorin JM, Murteira S, Hansen K, Toumi M. Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis. BMC Psychiatry 2008;8:8-16
71. Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psych Clin Pract 2002;6(Suppl 1):S53-9 •• An outstanding review of mortality issues and postmarketing surveillance studies on sertindole.
72. Wilton LV, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001;15:120-6
73. Muldoon C, Cochran J. Mortality rates in three comparative cohorts of patients who received sertindole, olanzapine or risperidone: a hospital-based, retrospective study. J Outcomes Res 2006;10:47-55
74. Peuskens J, Moore N, Azorin JM, et al. The European sertindole safety and exposure survey: a follow-up study of 8 600 patients. Pharmacoepidemiol Drug Saf 2007;16:804-11
75. Kasper S, Moller HJ, Hale A. The European Post-Marketing Observational Sertindole Study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 2010;260:59-68
76. Sturkenboom MCJM, Picelli G, Moore N. Mortality during use of sertindole and other anti-psychotics in the Netherlands and Belgium [abstract 273]. Pharmacoepidemiol Drug Saf 2001;10:S1-164
77. Lancon C, Toumi M, Sapin C, Hansen K. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe. BMC Psychiatry 2008;8:57
78. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
79. Ucok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry 2008;7:58-62
80. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
81. Strom BL, Faich GA, Reynolds RF, et al. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. J Clin Psychiatry 2008;69:114-21
82. Eng SM, Strom BL, Faich GA, et al. Comparative mortality associated with ziprasidone versus olanzapine in real world use: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Schizophr Res 2008;98(Suppl 1):160-1
83. Kasper S, Hale A, Azorin JM, Moller HJ. Benefit-risk evaluation of olanzapine risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 2):2-14
84. Toumi M, De Jonghe D. Assesment of potential risk of occurrence of torsades de pointe in sertindole-treated patients, and identification of potential risk factors for QTc interval prolongation. H Lundbeck A/S, internal report, 1998
85. Nielsen J, Andersen MP, Graff C, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010;121:385-8
86. Nielsen J, Graff C, Hardahl T, et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009;19:702-7
87. Crocq MA, Naber D, Lader MH, et al. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol 2010;20:829-38
88. Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev 2005;3:CD001715
89. Perquin LN. Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol 2005;20:335-8
90. De Hert M, Mittoux A, He Y, Peuskens J. A head-to-head comparison of sertindole and risperidone on metabolic parameters. Schizophr Res 2010;123:276-7
91. De Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci 2010. [Epub ahead of print]
92. Launois R, Graf von der Schulenburg, Knapp M, Toumi M. Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model. Int J Psychiatry Clin Pract 1998;2(Suppl 2):S79-86
93. Dordzinski WJ, Paulik D, Nogas G. Cost-utility and budget impact of sertindole in the treatment of schizophrenia in Poland. ISPOR 11th Annual European Congress, 8-11 November 2008; Athens, Greece
94. Hansen K, Launois R, Sapin C. Pharmacoeconomic positioning of sertindole among atypical antipsychotics in the management of schizophrenia in Turkey. International Health Economics Association (iHEA) 2007, 6th World Congress: Explorations in Health Economics Paper
95. Wirshing DA, Meyer JM. Obesity in patients with schizophrenia. In: Meyer JM, Nasrallah HA, editors, Medical illness and schizophrenia. American Psychiatric Publishing, Washington, DC; 2003. p. 35-51
96. Henderson DC, Powers Ettinger E. Glucose intolerance and diabetes in schizophrenia. In: Meyer JM, Nasrallah HA, editors, Medical illness and schizophrenia. American Psychiatric Publishing, Washington DC; 2003. p. 99-114
97. Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003;12:271-81
98. Schuck P, van den Ameele M, Jaanson P. Case histories illustrating the utility of sertindole in clinical practice. CNS Drugs 2004;18(Suppl 2):31-40
99. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first episode psychosis. Arch Gen Psychiatry 2005;62:361-70